Evidence map›Paper›PMID 36499587›Full record

ArticleInternational journal of molecular sciences2022

Detection of SARS-CoV-2 Virus by Triplex Enhanced Nucleic Acid Detection Assay (TENADA).

Anna Aviñó, Carlos Cuestas-Ayllón, Manuel Gutiérrez-Capitán, Lluisa Vilaplana, Valeria Grazu, Véronique Noé, Eva Balada, Antonio Baldi, Alex J Félix, Eva Aubets and 8 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Targeting MYC Regulation with Polypurine Reverse Hoogsteen Oligonucleotides.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Anna AviñóInstitute for Advanced Chemistry of Catalonia (IQAC), Consejo Superior de Investigaciones Científicas (CSIC), 08034 Barcelona, Spain.ORCID 0000-0003-3047-738X
Carlos Cuestas-AyllónCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28220 Madrid, Spain.
Manuel Gutiérrez-CapitánInstituto de Microelectrónica de Barcelona (IMB-CNM), Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193 Cerdanyola, Spain.ORCID 0000-0002-7347-1765
Lluisa VilaplanaInstitute for Advanced Chemistry of Catalonia (IQAC), Consejo Superior de Investigaciones Científicas (CSIC), 08034 Barcelona, Spain.ORCID 0000-0002-9982-6704
Valeria GrazuCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0001-6170-4237
Véronique NoéDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, University of Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0001-7937-8038
Eva BaladaInstitute for Advanced Chemistry of Catalonia (IQAC), Consejo Superior de Investigaciones Científicas (CSIC), 08034 Barcelona, Spain.ORCID 0000-0002-3059-0633
Antonio BaldiInstituto de Microelectrónica de Barcelona (IMB-CNM), Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193 Cerdanyola, Spain.ORCID 0000-0002-8198-8529
Alex J FélixDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, University of Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0002-7145-7169
Eva AubetsDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, University of Barcelona (UB), 08028 Barcelona, Spain.
Simonas ValiuskaDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, University of Barcelona (UB), 08028 Barcelona, Spain.
Arnau DomínguezInstitute for Advanced Chemistry of Catalonia (IQAC), Consejo Superior de Investigaciones Científicas (CSIC), 08034 Barcelona, Spain.ORCID 0000-0002-4336-9209
Raimundo GargalloDepartment of Chemical Engineering and Analytical Chemistry, University of Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0001-8716-8356
Ramon EritjaInstitute for Advanced Chemistry of Catalonia (IQAC), Consejo Superior de Investigaciones Científicas (CSIC), 08034 Barcelona, Spain.ORCID 0000-0001-5383-9334
M-Pilar MarcoInstitute for Advanced Chemistry of Catalonia (IQAC), Consejo Superior de Investigaciones Científicas (CSIC), 08034 Barcelona, Spain.
César Fernández-SánchezCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0003-2779-9281
Jesús Martínez de la FuenteCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28220 Madrid, Spain.
Carlos J CiudadDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, University of Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0002-7855-392X
Consejo Superior de Investigaciones Científicas · ESInstitut de Nanociència i Nanotecnologia de la Universitat de BarcelonaUniversitat de Barcelona · ES

Funding

Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine CB06/01/0019Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine CB06/01/00263La Marató de TV3 Foundation 202110-30-31-32-33Spanish Ministry of Science and Innovation PID2019-107158GB-I00Spanish Ministry of Science and Innovation PID2020-118145RB-I00Spanish Ministry of Science and Innovation PID2021-122271OB-I00Spanish National Research Council CSIC-COV19-041
6 · The paper itself

Abstract

SARS-CoV-2, a positive-strand RNA virus has caused devastating effects. The standard method for COVID diagnosis is based on polymerase chain reaction (PCR). The method needs expensive reagents and equipment and well-trained personnel and takes a few hours to be completed. The search for faster solutions has led to the development of immunological assays based on antibodies that recognize the viral proteins that are faster and do not require any special equipment. Here, we explore an innovative analytical approach based on the sandwich oligonucleotide hybridization which can be adapted to several biosensing devices including thermal lateral flow and electrochemical devices, as well as fluorescent microarrays. Polypurine reverse-Hoogsteen hairpins (PPRHs) oligonucleotides that form high-affinity triplexes with the polypyrimidine target sequences are used for the efficient capture of the viral genome. Then, a second labeled oligonucleotide is used to detect the formation of a trimolecular complex in a similar way to antigen tests. The reached limit of detection is around 0.01 nM (a few femtomoles) without the use of any amplification steps. The triplex enhanced nucleic acid detection assay (TENADA) can be readily adapted for the detection of any pathogen requiring only the knowledge of the pathogen genome sequence.

Indexed as

COVID-19Nucleic AcidsHumansNucleic Acid Amplification TechniquesOligonucleotidesPolymerase Chain ReactionRNA, ViralSARS-CoV-2Nucleic AcidsOligonucleotidesRNA, ViralCOVID diagnosiselectrochemical magnetoassayfluorescent microarrayPolypurine reverse-Hoogsteen hairpinSARS-CoV-2 RNA detectionthermal lateral flow

Identifiers

PMID36499587
PMCPMC9740288
OpenAlexW4310716535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.